Arbutus Biopharma Corporation (NASDAQ: ABUS) started the day on March 16, 2023, with a price decrease of -2.97% at $2.94. During the day, the stock rose to $3.0235 and sunk to $2.91 before settling in for the price of $3.03 at the close. Taking a more long-term approach, ABUS posted a 52-week range of $1.85-$3.22.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
The Healthcare sector firm’s twelve-monthly sales growth has been 29.50% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was 24.40%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 44.70%. This publicly-traded company’s shares outstanding now amounts to $155.60 million, simultaneously with a float of $116.15 million. The organization now has a market capitalization sitting at $483.10 million. At the time of writing, stock’s 50-day Moving Average stood at $2.79, while the 200-day Moving Average is $2.50.
It is quite necessary to find out the efficiency of the corporate organization, which has 96 number of employees on its payroll. For the Profitability, stocks gross margin was +96.34, operating margin was -162.03 and Pretax Margin of -166.62.
Arbutus Biopharma Corporation (ABUS) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Arbutus Biopharma Corporation’s current insider ownership accounts for 25.66%, in contrast to 30.00% institutional ownership.
Arbutus Biopharma Corporation (ABUS) Earnings and Revenue Records
In the latest quarterly report released, which was put into the public domain on 9/29/2022, the organization reported -$0.12 earnings per share (EPS) for the three months, surpassing the consensus estimate (set at -$0.13) by $0.01. This company achieved a net margin of -178.01 while generating a return on equity of -45.35. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.14 per share during the current fiscal year.
Arbutus Biopharma Corporation’s EPS increase for this current 12-month fiscal period is 44.70% and is forecasted to reach -0.65 in the upcoming year.
Arbutus Biopharma Corporation (NASDAQ: ABUS) Trading Performance Indicators
Let’s observe the current performance indicators for Arbutus Biopharma Corporation (ABUS). It’s Quick Ratio in the last reported quarter now stands at 4.60. The Stock has managed to achieve an average true range (ATR) of 0.13. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 12.39.
In the same vein, ABUS’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.46, a figure that is expected to reach -0.14 in the next quarter, and analysts are predicting that it will be -0.65 at the market close of one year from today.
Technical Analysis of Arbutus Biopharma Corporation (ABUS)
If we take a close look at the recent performances of Arbutus Biopharma Corporation (NASDAQ: ABUS), its last 5-days Average volume was 1.56 million that shows progress from its year to date volume of 0.92 million. During the previous 9 days, stock’s Stochastic %D was recorded 82.22% While, its Average True Range was 0.14.
Raw Stochastic average of Arbutus Biopharma Corporation (ABUS) in the period of the previous 100 days is set at 86.54%, which indicates a major rise in contrast to 72.55% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 39.34% that was lower than 53.96% volatility it exhibited in the past 100-days period.